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Abstract. Dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr) alleles were typed in 67 Malaysian
Plasmodium falciparum isolates. The isolates were collected from two geographically distinct locations: 51 from
Sabah, Malaysian Borneo, where sulfadoxine/pyrimethamine (SDX/PYR) is used to treat uncomplicated malaria and
16 from Peninsular Malaysia wherein vivo resistance to SDX/PYR has been reported. A total of sevendhps alleles
were identified with no significant difference in allele frequency between the 2 populations. Two of thedhps alleles
described here have not been previously reported. Fourdhfr alleles were detected in 67P. falciparum isolates. Eighty-
seven percent of the isolates from the Peninsula, where clinical SDX/PYR failure has been reported, haddhfr alleles
with triple point mutations while all of the isolates from Sabah haddhfr alleles with 2 or less point mutations. The
difference indhfr allele frequency between the two populations was highly significant. There was no correlation
betweenin vitro PYR response and accumulation ofdhfr point mutations.
Fansidar, sulfadoxine/pyrimethamine (SDX/PYR) anti-
malarial combination therapy, has been used to treat uncom-
plicated Plasmodium falciparum malaria in areas where
there is chloroquine resistance. Sulfadoxine and pyrimeth-
amine inhibit different enzymes in the folate biosynthetic
pathway, dihydropteroate synthase (dhps) and dihydrofolate
reductase (dhfr) respectively, and act synergistically when
used in combination.1 In endemic areas where SDX/PYR
treatment has replaced chloroquine, clinical drug failure has
been reported at various intervals following SDX/PYR in-
troduction.2 Clinical performance of antimalarial treatment
may be measured byin vivo drug response assays and esti-
mated byin vitro drug sensitivity assays. It is difficult to
measure the response to the SDX/PYR combinationin vi-
tro3,4 and thein vitro response to the PYR moiety alone has
been used to indicate potential resistance to the SDX/PYR
combination therapy.5
Non-silent point mutations on thedhps and dhfr genes
have been reported following the introduction of SDX/PYR
therapy.6–8 The dhfr mutations have been shown to alter the
PYR-dhfr association constant reducing the efficiency of the
drug in vitro.9 In addition there appears to be a sequential
progression in the number of mutations on thed fr gene that
correlate with an increased incidence of clinical drug failure
and reduced responsein vitro. The point mutation atdhfr
position 108 is detected first, followed by point mutations at
positions 50 and/or 59 and finally position 164.2,10,11 For
dhps, mutations have also been detected following SDX/
PYR therapy.2,6,12 The evidence for sequentialdhps muta-
tional events is not as strong but the point mutation at po-
sition 437 is thought to be the first event and is associated
with a decreased response to SDX.6,7 SDX/PYR has been in
use for more than 20 years in Malaysia. The epidemiology
of malaria in Malaysia, shows a contrast between Peninsular
Malaysia on mainland Asia and the states of Sabah and Sa-
rawak on the island of Borneo. Malaria is largely under con-
trol in Peninsular Malaysia despite the fact that clinical re-
sistance to SDX/PYR has been reported in various loca-
tions.13 However, in Sabah (Malaysian Borneo), SDX/PYR
remains the drug of choice for treating uncomplicated fal-
ciparum malaria. That the drug has been used for such a
prolonged period in Sabah without the widespread emer-
gence of clinical failure is unusual given that resistance to
SDX/PYR has emerged rapidly in Southeast Asian (includ-
ing Peninsular Malaysia), South American, and African
countries.2,14,15 In this study, point mutations on thedhps and
dhfr genes were typed inP. falciparum isolates collected
from Kelantan, Peninsular Malaysia where clinical resistance
to SDX/PYR has been reported13 and from Sabah where
SDX/PYR remains the recommended drug of choice for un-
complicated malaria.Dhps anddhfr alleles were mapped and
the potential of molecular typing as a marker for emergent
drug resistance is discussed.
MATERIALS AND METHODS
The study was conducted onP. falciparum isolates col-
lected from patients at Lahad Datu Hospital, Kunak Health
Center, and Tawau General Hospital, in Southern Sabah, Ma-
laysian Borneo during December 1996, May 1997, and De-
cember 1997. Patients with slide-positiveP. falciparum sin-
gle infections were recruited into the study following a full
explanation of the study protocol and having obtained pa-
tient or parent/guardian consent.
Three ml venous blood were collected of which 0.5 ml
was placed into heparin tubes for World Health Organization
(WHO) in vitro drug assays and the remainder into EDTA
blood collection tubes. The EDTA blood was used for mak-
ing thick and thin blood films, 10 20 l bloods spots on
filter paper and the remainder cryopreserved. In addition,
blood-spot samples from Peninsula Malaysia were included
in the molecular typing study. These samples were collected
between August 1994 and August 1995 from two district
hospitals, namely Tanah Merah and Kuala Krai in the state
of Kelantan situated on the Eastern Malaysian/Thai border.
The study protocol was approved by the Ethics Committee
of the Ministry of Health Malaysia.
For mutation detection, DNA was extracted from 20l of
